08:44 AM EDT, 07/21/2025 (MT Newswires) -- UroGen Pharma ( URGN ) said Monday that Zusduri demonstrated durable, long-term complete responses in patients with low-grade intermediate-risk non-muscle invasive bladder cancer, citing results from a five-year extension study of its phase 2b Optima II trial.

The biotechnology company said the findings showed that patients remained event-free for a two-year median after achieving complete response with Zusduri.

Shares were 1.5% higher in recent premarket activity.